Explore the coverage
Center · The Hill News
Bias ratings describe an outlet's overall coverage—not whether this particular article is accurate.
FDA approves first mRNA flu vaccine
The Food and Drug Administration (FDA) late Wednesday approved the nation’s first mRNA flu vaccine, manufactured by drugmaker Moderna. The agency approved the shot for two separate age groups; people age 50 to 64, and for 65 years and older. Moderna said it will conduct a postmarket clinical trial to confirm the effectiveness in the…
Read at The Hill NewsChoose a story to feature it above.
6 independent news outlets covered this story, with reporting from the left, center, and right.
Across these headlines, common terms include mrna, vaccine, approves, first, moderna.
Open a headline at its original source, or choose “Show as featured story” to compare it above.
Center Left · US news | The Guardian
Center · The Hill News
Center Left · NYT > U.S. > Politics
Center · NewsNation
Center Left · TIME
3 publishers
The mFlusiva vaccine for older people is first made with mRNA platform key to ending coronavirus pandemicThe Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, Moderna, the manufacturer, said.The shot, named mFlusiva, is intended for adults aged 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late on Wednesday that it expected some of its new version to be available soon at select retailers. Continue reading...
The agency had initially refused to even review the application but reversed course after a public outcry.
The shot, made by Moderna, will be available for this year's upcoming flu season.
2 publishers
The Food and Drug Administration (FDA) late Wednesday approved the nation’s first mRNA flu vaccine, manufactured by drugmaker Moderna. The agency approved the shot for two separate age groups; people age 50 to 64, and for 65 years and older. Moderna said it will conduct a postmarket clinical trial to confirm the effectiveness in the…
The agency approved the shot for two separate age groups: People age 50 to 64, and for 65 years and older.
1 publisher
